These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 29016288)

  • 1. Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India.
    Pandey K; Pal B; Siddiqui NA; Rabi Das VN; Murti K; Lal CS; Verma N; Babu R; Ali V; Kumar R; Das P
    Am J Trop Med Hyg; 2017 Nov; 97(5):1498-1502. PubMed ID: 29016288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
    Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
    N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.
    Pandey K; Pal B; Siddiqui NA; Lal CS; Ali V; Bimal S; Kumar A; Verma N; Das VNR; Singh SK; Topno RK; Das P
    Indian J Dermatol Venereol Leprol; 2021; 87(1):34-41. PubMed ID: 33580944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.
    Sundar S; Agrawal G; Rai M; Makharia MK; Murray HW
    BMJ; 2001 Aug; 323(7310):419-22. PubMed ID: 11520836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study.
    Mondal D; Alvar J; Hasnain MG; Hossain MS; Ghosh D; Huda MM; Nabi SG; Sundar S; Matlashewski G; Arana B
    Lancet Glob Health; 2014 Jan; 2(1):e51-7. PubMed ID: 25104636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.
    Sundar S; Jha TK; Thakur CP; Mishra M; Singh VR; Buffels R
    Am J Trop Med Hyg; 2002 Feb; 66(2):143-6. PubMed ID: 12135284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study.
    Sundar S; Singh A; Rai M; Chakravarty J
    Am J Trop Med Hyg; 2015 Mar; 92(3):513-7. PubMed ID: 25510715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.
    Tamiru A; Tigabu B; Yifru S; Diro E; Hailu A
    BMC Infect Dis; 2016 Oct; 16(1):548. PubMed ID: 27724891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study.
    Thakur CP; Pandey AK; Sinha GP; Roy S; Behbehani K; Olliaro P
    Trans R Soc Trop Med Hyg; 1996; 90(3):319-22. PubMed ID: 8758093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observations on amphotericin B treatment of kala-azar given in a rural set up in Bihar, India.
    Thakur CP; Ahmed S
    Indian J Med Res; 2001 Jan; 113():14-8. PubMed ID: 11280166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.
    Sinha PK; Roddy P; Palma PP; Kociejowski A; Lima MA; Rabi Das VN; Gupta J; Kumar N; Mitra G; Saint-Sauveur JF; Seena S; Balasegaram M; Parreño F; Pandey K
    Am J Trop Med Hyg; 2010 Aug; 83(2):357-64. PubMed ID: 20682882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
    Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Single-Dose Liposomal Amphotericin B in Visceral Leishmaniasis in Bihar.
    Sundar S; Singh A; Agrawal N; Chakravarty J
    Am J Trop Med Hyg; 2019 Oct; 101(4):795-798. PubMed ID: 31436156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome
    Goswami RP; Rahman M; Das S; Tripathi SK; Goswami RP
    Am J Trop Med Hyg; 2020 Jul; 103(1):308-314. PubMed ID: 32394874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-course Regimens of Liposomal Amphotericin B for the Treatment of Mediterranean Visceral Leishmaniasis in Children: An 11-year Retrospective Study at a Tertiary Care Center.
    Krepis P; Argyri I; Krepi A; Syrmou A; Spyridis N; Tsolia M
    Pediatr Infect Dis J; 2017 Sep; 36(9):849-854. PubMed ID: 28399053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.